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α-Synuclein aggregation and ﬁbrillation are closely associated with the formation of Lewy bodies in neurons and are implicated in
the causative pathogenesis of Parkinson’s disease and other synucleinopathies. Currently, there is no approved therapeutic agent
directed toward preventing the protein aggregation, which has been recently shown to have a key role in the cytotoxic nature of
amyloidogenic proteins. Flavonoids, known as plant pigments, belong to a broad family of polyphenolic compounds. Over 4,000
ﬂavonoids have been identiﬁed from various plants and foodstuﬀs derived from plants and have been demonstrated as potential
neuroprotective agents. In this study 48 ﬂavonoids belonging to several classes with structures diﬀering in the position of double
bonds and ring substituents were tested for their ability to inhibit the ﬁbrillation of α-synuclein in vitro. A variety of ﬂavonoids
inhibited α-synuclein ﬁbrillation, and most of the strong inhibitory ﬂavonoids were also found to disaggregate preformed
ﬁbrils.
1.Introduction
Parkinson’s disease (PD) is a chronic progressive disease,
characterized clinically by resting tremor, bradykinesia
(slowness in initiating movements), and rigidity. As only a
small number of cases are diagnosed before the age of 50,
PD is typically considered an aging disease, with a prevalence
of approximately 2% after the age of 65 [1]. The cause of
this neurodegenerative disease is still mysterious, although
considerable evidence suggests a multifactorial etiology
involving genetic susceptibility and environmental factors.
In PD, neuronal death is localized to dopaminergic
neurons in the substantia nigra region of the brain stem
and precedes appearance of symptoms. It is believed that
ca. 70% of neurons may have died by the time symptoms
become apparent [2]. Diagnosis can only be deﬁnitively
conﬁrmed post mortem, by histopathological examination
for the pigmented neuron loss and the presence of Lewy
bodies (LBs) and Lewy neuritis (LNs) [3]. LBs are spherical
protein inclusions found in the cytoplasm of surviving nigral
neurons consisting of a dense core surrounded by a halo of
radiating ﬁbrils of α-synuclein, the major component of LBs
[4]. A variety of other proteins have also been identiﬁed in
LBs [5, 6]. However, both the mechanism underlying the
formation of LBs and their pathogenic relevance are still
unclear [7, 8].
Substantial evidence suggests that the aggregation of α-
synuclein is a critical step in the etiology of PD [9–11]. The
following observations are among the most compelling for
the involvement of α-synuclein and its aggregation in PD:
(i) ﬁbrils of α-synuclein are observed in LBs and LNs, the
characteristic hallmarks of the PD pathology [4, 12, 13];
(ii) three missense mutations, A53T, A30P, and E46K in α-
synuclein, lead to familial early onset Parkinson’s disease
[14–16]; A53T and A30P were known to increase the aggre-
gationpropensityofα-synuclein[17,18];(iii)geneticstudies
have shown that several cases of familial early onset PD are
caused by overexpression of α-synuclein due to duplication
ortriplicationoftheα-synucleingenelocus(SNCA)[19,20].2 Parkinson’s Disease
Several possible mechanisms for the observed cyto-
toxicity of amyloidogenic assemblies have been suggested.
One mechanism suggests a direct eﬀect of amyloidogenic
assemblies on cell membrane structure and integrity,
either through the pore formation [21–26], or via the
destabilization of amyloidogenic bundles [27, 28].
Currently, no preventive therapy is available for PD.
It is believed that compounds that slow and/or prevent
aggregation and ﬁbrillation of α-synuclein could represent
potential drug leads for PD prevention. Therefore, many
of the latest therapeutic strategies are aimed at inhibiting
ﬁbril formation and at promoting ﬁbril clearance. They
include the use of antibodies, synthetic peptides, molecular
chaperones, and chemical compounds. In the past few years
small organic molecules, especially certain polyphenolic
compounds, have been extensively tested for their ability to
inhibit ﬁbril formation in vitro, particularly in relation to Aβ
deposition [29], the formation of protease-resistant forms of
the prion protein [30], the aggregation of huntingtin [31],
and the heparin-induced formation of tau ﬁlaments [32, 33].
An analysis of these reports shows that certain polyphenols
dramatically inhibit cell death in the amyloidogenic cytotox-
icity assays.
Less is known about eﬀects of polyphenols and other
small organic molecules on α-synuclein ﬁbril formation.
Only the antituberculosis drug rifampicin and Chinese
herbal drug baicalein from Scutellaria baicalensis have been
analyzed and shown to inhibit α-synuclein ﬁbrillation
[36–38].
Flavonoids have been known as plant pigments for over
ac e n t u r ya n db e l o n gt oab r o a dc l a s so fp o l y p h e n o l i c
compounds.Over4,000ﬂavonoidshavebeenidentiﬁedfrom
variousplants[39]andfoodstuﬀsderivedfromplants,form-
ing substantial constituents of the human diet. The intake
of ﬂavonoids is in the range of 50–800mg/day, depending
on the consumption of vegetables and fruits and of speciﬁc
beverages, such as red wine, tea, and unﬁltered beer [40].
Most of the ﬂavonoids are very potent antioxidants, which
has often been associated with their health-related eﬀect.
Due to their low redox potentials (0.23 < E7 < 0.75V) [41],
ﬂavonoids (Fl–OH) are thermodynamically able to reduce
highly oxidizing free radicals with redox potentials in the
range 2.13–1.0V [42], by hydrogen atom donation:
Fl–OH+R
• −→ Fl–O
• +RH (1 )
where R
• represents superoxide anion, peroxyl, alkoxyl, and
hydroxyl radicals [43–45]. The aroxyl radical (Fl–O
•)m a y
react with a second radical, acquiring a stable quinone
structure (Figure 1(b)). Scavenging of free radicals plays a
considerable role in the antioxidant activity of ﬂavonoid
compounds [46]. In recent years, ﬂavonoids, being potent
free radical scavengers, have attracted a tremendous interest
as possible therapeutics against free radical-mediated dis-
eases associated with the oxidative stress [47].
Oxidative stress is an imbalanced state where excessive
quantities of reactive oxygen species (ROS), such as superox-
ide radical anion, hydrogen peroxide, and hydroxyl radical,
are present at levels higher than required for normal cell
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Figure 1:(a)Basicstructureofaﬂavonoid,aC15-skeletonshowing
t h eA ,B ,a n dCr i n g ,r e p r o d u c e df r o m[ 34]. (b) Scavenging of ROS
(R
• ) by ﬂavonoids, reproduced from [35].
function and overwhelm endogenous antioxidant capacity
and repair [48, 49]. Oxidative stress has been linked to
cancer,aging,atherosclerosis,ischemicinjury,inﬂammation,
and neurodegenerative diseases such as Parkinson’s and
Alzheimer’s diseases [50–53].
As recently reviewed by Pietta [34], several attempts have
been made by numerous authors to establish the relationship
between ﬂavonoid structure and their radical-scavenging
activity [54–57]. In general, the radical-scavenging activities
of ﬂavonoids depend on the molecular structure and the
substitution pattern of hydroxyl groups, that is, on the
availability of phenolic hydrogens and on the possibility of
stabilization of the resulting phenoxyl radicals via hydro-
gen bonding or by expanded electron delocalization [58–
60]. Besides the radical scavenging activity, the ability of
ﬂavonoids to chelate (bind) metal ions also contributes to
their antioxidant activity in vitro. The proposed binding sites
for trace metals to ﬂavonoids are basically consistent with
the structural requirements for eﬀective radical scavenging,
suggesting that metal chelation and antioxidant activity are
intimately linked.
Oxidative stress, transition metal accumulation, and
inﬂammationappeartoplayaroleinthepathologyofseveral
neurodegenerative diseases, including Parkinson’s disease.
Accumulated evidence has suggested that dietary ﬂavonoids
could be potential neuroprotective agents. For example, the
consumption of ﬂavonoid-rich blueberries or strawberries
can reverse cognitive and motor behavior deﬁcits in rats
[62], and intake of antioxidant ﬂavonoids is associated with
a lower incidence of dementia [63]. EGCG, a ﬂavonoid
from green tea, has been shown to be neuroprotective in an
MPTP-induced animal model of dopaminergic degeneration
by Levites et al. [64]. The data from Griﬃoen et al.Parkinson’s Disease 3
also demonstrated that several ﬂavonoids counteract the
cytotoxic properties of α-synuclein aggregates directly in a
cellular context [65].
The properties of ﬂavonoids such as their abundance
in plants and human diet, variety in composition and
structure, and antioxidative and neuroprotective biological
activities make these compounds very attractive targets while
screening small organic molecules that can interact with α-
synuclein protein and inhibit its aggregation. These natural
chemical compounds can be potentially used as therapeutic
drugs in preventing of neurodegeneration in Parkinson’s dis-
ease. Therefore, we analyzed a ﬂavonoid library containing
48 compounds from several classes for their ability to inhibit
α-synuclein ﬁbril formation in vitro. Many ﬂavonoids were
shown to inhibit α-synuclein ﬁbrillation and aggregation.
Importantly, the majority of the strong inhibitors also
disaggregate the preformed ﬁbrils.
2.MaterialsandMethods
2.1. Materials. All ﬂavonoids were obtained from IND-
OFINE chemical Co., Inc. Thioﬂavin T (ThT) was obtained
from Sigma-Aldrich. All other chemicals were analyti-
cal grade and obtained from Fisher chemicals or VWR
scientiﬁc.
2.2. Expression and Puriﬁcation of α-Synuclein. Wild type
(WT) human recombinant α-synuclein-containing plasmid
pRK172 (obtained from R. Jakes and M. Goedert) was
transfectedintoEscherichiacoliBL21(DE3)cells.Proteinwas
induced and puriﬁed as described previously [66]. Protein
concentration was determined spectrophotometrically.
2.3. Aggregation/Fibrillation Studies and ThT Assays.
Lyophylized α-synuclein was prepared for use by dissolution
at high pH (approximately 10.5) in dilute NaOH for 5 to
10 minutes and adjusted to pH 7.4 prior to centrifugation
at 95,000rpm with a Beckman Airfuge ultracentrifuge to
remove any aggregated material. A 5-fold dilution with
buﬀer (see text for speciﬁc conditions used) was followed
withadjustmenttothedesiredpH.Flavonoidsweredissolved
in DMSO to make a stock solution at a concentration of 5,
10, or 20mm and to make a ﬁnal solution of protein and
ﬂavonoid in 1% DMSO unless indicated otherwise. All of the
protein ﬁnal solutions consisted of PBS with 0.02% NaN3
added to avoid bacteria growth.
For plate assays, the protein solution (0.5mg/mL or
35μM) was mixed with ﬂavonoids to give a ﬁnal concentra-
tion of 50μM. Three replicates of each sample were prepared
in a 96-well plate with a volume of 120μLp e rw e l la n d
a 3mm Teﬂon bead to provide agitation (120rpm, 20mm
diameter). The assays were performed in a ﬂuorescent plate
reader (Labsystems Fluoroskan Ascent CF). Measurements
were taken at 30-minute intervals with excitation at 444nm
and emission monitored at 485nm.
For manual assays, the protein solution (1mg/mL or
70μM) was mixed with ﬂavonoids to give a ﬁnal concen-
tration of 100μM. Protein samples were stirred at 37◦C
with a mini-Teﬂon stir bar. Aliquots of 5 or 10μLw e r e
removed from the incubated solution and added to 1mL
of 10μM ThT solutions in 20mm phosphate buﬀer (pH
7.4) as a function of time to monitor the ﬁbrillation
kinetics. ThT ﬂuorescence was recorded at 482nm with
excitation at 450nm and slits of 5nm for both excitation and
emission using a FluoroMax-3 spectroﬂuorometer (Jobin
Yvon Horiba).
2.4. Electron Microscopy Measurements. Transmission elec-
tron microscopy (TEM) was used to estimate the size
and structural morphology of α-synuclein. Aliquots of 5μL
sample were deposited on Formvar-coated 300 mesh copper
grids (Ted Pella) and incubated for 5 to 10 minutes. Salts
were washed out with distilled water, and samples were
dried, negatively stained with 1% (w/v) uranyl acetate,
and visualized on a JEOL JEM-100B transmission electron
microscopy operated at 80kV. Typical magniﬁcations ranged
from ×75,000 to 300,000. The grids were thoroughly exam-
ined to obtain an overall evaluation of the samples. Images
were produced with Gattan Digital Micrograph software.
2.5. Electrophoresis. Sodium Dodecyl Sulfate Polyacrylamide
Gel Electrophoresis (SDS-PAGE) was carried out on an
Amersham Phast System Separation and Control Unit with
PhastGel Gradient 8-25 polyacrylamide gels. SDS buﬀer
(0.20M tricine, 0.20M Tris, 0.55% SDS, pH 8.1) strips
(Amersham) were used. Gel electrophoresis samples were
prepared by the addition of 3 parts of protein solution to 1
part SDS buﬀer (0.25M Tris, 8% SDS, 60% glycerol, 0.08%
bromophenol blue, pH 6.8) and boiled for 3–5 minutes.
The 10–225kDa protein markers were purchased from USB
Corporation (Cleveland, Ohio, USA).
Isoelectric Focusing (IEF) Polyacrylamide Gel- IEF-
Polyacrylamide Gel (4–6.5) was carried out on an Amer-
sham Phast System Separation and Control Unit with
IEF polyacrylamide gels. PI standards contain proteins as
follows:HumancarbonicanhydraseB:6.55;Bovinecarbonic
anhydrase B: 5.85; β-Lactoglobulin A: 5.20; Soybean trypsin
inhibitor: 4.55; Glucose oxidase mannitol: 4.15; Methyl red
(dye): 3.75; Amyloglucosidase: 3.50; Pepsinogen: 2.80.
2.6. Chromatography: Size Exclusion (SEC) HPLC Measure-
ments. An aliquot of each sample was removed from the
α-synuclein incubation at various times, and the insoluble
material was removed by centrifugation for 20 minutes at
14,000rpm. Sample volumes of 40μL of supernatant were
eluted from a TSK-GEL G4000SWXL size exclusion column
(7.8mm inner diameter × 30cm) in 20mm phosphate
buﬀer, pH 7.0, and 100mm Na2SO4 using a Waters 2695
separations module with a Waters 996 photodiode array
detector. The HPLC system was controlled, and data were
collected and analyzed by Millennium software. The col-
umn was eluted at a ﬂow rate of 0.5mL/min, and the
absorbance of the mobile phase was monitored over the
wavelength range from 220 to 450nm with a bandwidth
of 1.2nm. The retention times were calibrated with the
following protein molecular mass standards: ribonuclease4 Parkinson’s Disease
A (13.6kDa), chymotrypsinogen A (25kDa), ovalbumin
(43kDa), albumin (bovine serum) (67kDa), and aldolase
(158kDa). The void volume was determined with blue
dextran 2000 (∼2000kDa).
2.7. Electrospray Ionization Mass Spectrometry (ESI-MS).
Samples for mass spectrometry analysis were desalted with
C8 reverse phase column and eluted out with 80% ace-
tonitrile adjusted with TFA to a ﬁnal pH at 2.0. Injection
was carried out via a Harvard Apparatus (Holliston, MA)
s y r i n g ep u m pa taﬂ o wr a t eo f2 0 μL/min. Mass spectra
were obtained using Micromass ZMD electrospray mass
spectrometer operating in positive ionization mode. The
source temperature was set to 80◦C, and the capillary voltage
was 3.25kV. Protein molecular weight was determined from
m/z by Masslynx software.
3. Results andDiscussion
3.1. Eﬀects of Various Flavonoids on the Fibrillation
of α-Synuclein
3.1.1.FibrillationKineticsofWTα-SynucleininthePresenceof
Various Flavonoids. In this study, 48 ﬂavonoids belonging to
several classes with structures diﬀering in ring substituents
and in the nature/extent of alkylation have been tested
for their ability to inhibit the ﬁbrillation of α-synuclein in
vitro. These ﬂavonoids include 18 ﬂavones, 12 ﬂavonols, 4
ﬂavanones, 6 isoﬂavones, 2 dihydroﬂavonols, 3 catechins,
and 3 anthraquinones. Flavonols and ﬂavones accounted for
the majority of the study because of their wide distribution
in foods. Table S1 (see Table S1 in Supplementary Materials
available online at doi:10.1061/2010/650794.) lists the name,
synonym, and structure of the ﬂavonoid from each class. The
basic ﬂavonoid structure is the ﬂavan core, which consists
of a 15 carbon skeleton (C6-C3-C6), arranged in three rings
l a b e l e da sA ,B ,a n dCi nFigure 1(a) [34]. The various classes
of ﬂavonoids diﬀer in the level of oxidation and pattern of
substitution of the C ring, including ﬂavonols (quercetin and
kaempherol), ﬂavanols (the catechins), ﬂavones (apigenin),
and isoﬂavones (genistein). Individual compounds within a
class diﬀer in the pattern of substitution of the A and B rings.
Figure 2 represents kinetic proﬁles of α-synuclein ﬁbril
formation in the absence (circles) or presence of diﬀerent
ﬂavanoids, as monitored by changes in the ThT ﬂuorescence.
Diﬀerent ﬂavonoids aﬀected the α-synuclein ﬁbrillation to
ad i ﬀerent extend. Some ﬂavonoids, such as 22-357 and
22-344 (Figure 2, inverted triangles), slightly inhibited the
ﬁbrillationofα-synuclein,increasingthelagtime2-to3-fold
in comparison with that of the control, and were classiﬁed as
weak (+) inhibitors. Other ﬂavonoids, such as quercetin and
G-500(Figure 2,squares),signiﬁcantlyinhibitedα-synuclein
ﬁbrillation, with the lag time 4- to 5-fold longer than that of
the control, and were classiﬁed as good (++) inhibitors.
In the presence of 6-HP (Figure 2, diamonds), α-
synuclein ﬁbrillation was completely inhibited, as indicated
by the negligible changes in the ThT ﬂuorescence over the
time course. More importantly, no detectable α-synuclein
ﬁbrillation was observed for about 3 days or longer. The
inhibitory eﬀect of 6-HP on α-synuclein ﬁbrillation was as
good as that from baicalein (Figure 2), which was reported
earlier by Zhu et al. [36]. Besides 6-HP, several other
new ﬂavonoids from diﬀerent classes including eriodictoyl,
22-324, myricetin, EGCG, T-415, 22-340/tricetin, and 22-
341, also exhibited strong inhibitory eﬀects on α-synuclein
ﬁbrillation. Flavonoids that completely inhibited the ﬁbril
formation of α-synuclein under the current experimental
conditions were classiﬁed as strong inhibitors (designated as
+++). The inhibitory activities of each ﬂavonoid analyzed
in this study are listed in Table S1 (see Supplementary
Table S1).
In general, the intensity of ThT ﬂuorescence was pro-
portional to the amount of ﬁbril forms. For instance, in
the presence of the inhibitory ﬂavonoids, the ﬂuorescence
intensity at the end of reaction was in the decreasing
order: control (no ﬂavanoid) > 22-257 > quercetin > 6-HP.
EM analysis revealed that the detectable amount of ﬁbrils
formed at the end of the reaction was decreasing in the
same order. In the plate assays, however, most of the tested
compounds gave artiﬁcially low ThT signal. For example, in
thepresenceofsomeﬂavonoids,suchaswogonin,diosmetin,
and tamarixetin (Figure 3), the ThT ﬂuorescence intensity
was much lower than the control, whereas the kinetics of α-
synucleinﬁbrillationstillexhibitedatypicalsigmoidalshape,
with the lag time similar to the control. Since the amount
of ﬁbrils formed at the end of reaction was found to be
similartothatofthecontrol,asindicatedbytheEMimaging,
the lower ThT ﬂuorescence intensity for samples containing
these ﬂavonoids suggested that ﬂavanoids either quenched
the ThT ﬂuorescence or competed with ThT at the binding
siteontheproteinﬁbrils.Therefore,nomatterhowmuchthe
ﬂavonoids diminished the ThT ﬂuorescence, as long as they
did not prolong the lag time of α-synuclein ﬁbrillation, such
as 19-612, chrysoeriol, wogonin, and tamarixetin, and they
were all classiﬁed as noninhibitors (designated as −).
The quenching/competition was veriﬁed by titrations of
ﬁbril-ThT complex with various ﬂavonoids. The increasing
concentrations of ﬂavonoids from diﬀerent classes were
added to a certain amount of existing ﬁbrils in the presence
of 10μM ThT solution. The intensity of ThT ﬂuorescence in
the presence of ﬁbrils decreased as a function of ﬂavanoid
added and approached a certain saturation level when the
concentration of the ﬂavonoid was around 50μM( Figure 4).
The decrement degree was dependent on the number and
the arrangement of hydroxyl groups for ﬂavonoids from
thesameclass(e.g.,ﬂavanones:homoeriodictyol, hesperetin,
and eriodicyol) and on the level of saturation of Ring C
for ﬂavonoids from diﬀerent classes but with comparable
structures (e.g., ﬂavanones with 2, 3 double bond in Ring C
compared with the corresponding ﬂavones).
Figure S2 (see Supplementary Figure S2) shows instant
changes in the ThT ﬂuorescence intensity measured in the
presence of α-synuclein ﬁbrils and 50μM ﬂavonoids. The
addition of several ﬂavonoids, such as 6-HP, myricetin, G-
500, and emodin, resulted in almost 20-fold decrease in the
ThT ﬂuorescence intensity in comparison with the control
signal.Parkinson’s Disease 5
0
200
400
600
T
h
T
ﬂ
u
o
r
e
s
c
e
n
c
e
02 0 4 0 6 0 8 0
Time (h)
Synuclein
+ weak inhibitor (22-357, 22-344)
+ good inhibitor (quercetin, G-500)
+ strong inhibitor (6-HP, baicalein)
Figure 2: Inhibitory eﬀects of ﬂavonoids on the kinetics of
α-synuclein ﬁbrillation. Comparison is made between strong
inhibitors(+++),suchas6-HPandBaicalein,goodinhibitors(++),
such as quercetin and G-500, and weak inhibitors (+), such as 22-
357 and 22-344.
0
50
100
150
200
F
l
u
o
r
e
s
c
e
n
c
e
02 0 4 0 6 0 8 0
Time (h)
Synuclein 1% DMSO
+ 19-612
+c h r y s o e r i o l
+ homoeriodictyol
+ diosmetin
+ wogonin
+h e s p e r e t i n
+i s o r h a m n e t i n
+ tamarixetin
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To avoid interference of ﬂavonoids on ThT ﬂuorescence,
manual ThT assays were employed. The ﬁnal ratio of
ﬂavonoid to ThT in the manual assay was lower (about
1:10) compared with that in the plate assay; therefore the
quenching by ﬂavonoids was almost completely eliminated.
Figure 5 compares the results of the plate assay and the man-
ual assay for the ﬁbrillation of α-synuclein in the presence
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Structures of the ﬂavonoids are listed on the right side. ThT
concentration: 10μM. Cuvette volume: 1mL. With excitation at
450nm, ﬂuorescence emission at 482nm was measured upon the
addition of ﬂavonoid.
of one of the non-inhibitory ﬂavonoids, tamarixetin. In the
plate assay, ThT ﬂuorescence intensity in the presence of
50μM tamarixetin was much lower (∼10-fold) than that
in the absence of the ﬂavonoid, whereas in the manual
assay, the addition of 50μM tamarixetin did not aﬀect
ThT ﬂuorescence intensity (Figure 5). Similar results were
obtained when manual ThT assays were performed with
other non-inhibitory ﬂavonoids (data not shown).
All potential inhibitory ﬂavonoids identiﬁed in high-
throughput plate-reader assays were tested in subsequent
manual assays. In addition, the presence of ﬁbrils was6 Parkinson’s Disease
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Figure 5: The eﬀect of tamarixetin on the ThT ﬂuorescence of α-
synuclein ﬁbrillation by two ThT assays: the plate reader assay (a)
and the manual assay (b).
evaluated by EM and quantitatively estimated from SDS
PAGE of supernatant fractions (described below).
3.2. Analysis of α-Synuclein Species Formed in the Presence
of Flavonoids. During storage or incubation, monomeric α-
synuclein tends to self-associate into complexes of various
degrees including dimers, trimers, oligomers of various
size and shapes, protoﬁbrils, and ﬁbrils. Based on EM,
DLS, SEC, and SDS-PAGE, the typical distribution of α-
synuclein species after 3 days of incubation was 75%–
85% of ﬁbrils, 5%–10% of protoﬁbrils, and 5%–20% of
oligomeric species and amorphous aggregates. The non-
inhibitory ﬂavonoids did not aﬀect the distribution and
(a)
0.2μm
(b)
0.2μm
(c)
Figure 6: TEM images of α-synuclein samples after 3 days of
incubation in the absence (a) and presence of weak/good (b) and
strong (c) inhibitors of α-synuclein ﬁbrillation.
morphology of ﬁbrils (Figure 6(a)). Typical ﬁbrils were
10 ± 1nm in width and up to about 2μm in length.
Flavonoids classiﬁed as weak or good inhibitors decreased
ﬁbril amounts. Remained ﬁbrils were shorter in length but
similar in width (Figure 6(b)). When α-synuclein was incu-
bated with strong inhibitory ﬂavonoids only oligomers and a
few protoﬁbrils instead of ﬁbrils were detected (Figure 6(c)).
Flavonoid-induced protoﬁbles were 5–10 times shorter in
length and twice smaller in width compared with the typical
α-synucleinﬁbrils.Flavonoid-inducedoligomersappearedasParkinson’s Disease 7
round- or oval-shaped species with a 10–20nm diameter.
Their morphology was similar to the oligomeric species
observed in the absence of ﬂavonoids; however, the detailed
structureandassemblycouldbediﬀerent.Unfortunately,this
is beyond the detection limits of AFM and EM. Inhibitory
ﬂavonoids greatly aﬀected the distribution of aggregated α-
synuclein species apparently by stabilizing monomeric and
oligomeric species.
The distribution and stability of soluble species of α-
synuclein were analyzed by SEC and SDS-PAGE. In addition,
SDS PAGE was employed to quantitatively estimate the
amount of protein in the supernatant and pellet fractions
because Lowry and other spectrophotometric methods
could not be used due to ﬂavonoid interference with the
absorbance. Figure 7(a) shows SDS-PAGE of supernatant
fractions of α-synuclein samples incubated in the absence
or presence of the strong inhibitory ﬂavonoids. In the
control lane, a weak band of monomeric α-synuclein was
observed indicating that most of the protein was insoluble.
No dimers or oligomers were detected. In the presence of
non-inhibitory ﬂavonoids such as H-114 and 22-323, there
was also a relatively weak band of monomeric α-synuclein
in the gel (Figure 7(b)), similar to that of the control further
conﬁrming that these ﬂavonoids did not aﬀect α-synuclein
ﬁbrillation. On the other hand in the presence of strong
inhibitory ﬂavonoids such as 6-HP and 22-324, essentially all
of the protein was present in the supernatant. The monomer
bandwasmuchintensethanthatofthecontrol.Importantly,
higher molecular weight species were also detected on SDS
gel. They correspond to dimers (35kDa band), trimers
(50kDa band), and oligomers (a band on the top of the gel).
The oligomeric species and dimer/trimers were resistant to
treatment with SDS at 100◦C for 20 minutes. They were also
extremely stable in 8M urea and 6M GdmHCl (data not
shown).Thestabilityoftheseoligomersanddimersindicates
that they are diﬀerent from the similar species formed in the
absence of ﬂavonoids, which are unstable in the mentioned
conditions. The extreme stability can be due to very strong
noncovalent interactions and/or covalent binding.
The soluble forms of α-synuclein stabilized by the
ﬂavonoids were further analyzed by size exclusion HPLC.
The elution proﬁle of α-synuclein control sample showed
only one peak at 11.5mL corresponding to a trace amount of
monomers(Figure 8,blackcurves).Theseresultswererather
unexpected as EM, AFM, and DLS analyses revealed that
oligomers constituted the majority of the supernatant frac-
tions (data not shown). This contradiction can be explained
by the instability of oligomers under HPLC condition and by
theirfastdissociationupondilutionduringchromatographic
process. On the contrary, SEC analysis revealed that soluble
fractions of α-synuclein incubated with ﬂavonoids contained
signiﬁcant amounts of oligomers. Oligomeric fractions of α-
synuclein were obtained by running FPLC, which required
much more protein for analysis and was used only for some
ﬂavonoid-protein samples (data not shown). The elution
proﬁles of α-synuclein incubated in the presence of non-
inhibitory ﬂavonoids such as wogonin and kaempferol were
similar to the control proﬁle (Figure 8(b)). Peaks eluted
after the monomer peak (13.5 and 14mL) corresponded
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Figure 7: (a) SDS-PAGE from the supernatants of the incubated
samples of α-synuclein in the absence and presence of the strong
inhibitory ﬂavonoids. (b) Comparison of the eﬀect of strong
inhibitory ﬂavonoids (6-HP, 22-324) with noninhibitory ﬂavonoids
(H-114, 22-323) on formation of stabilized soluble species.
to polymerized forms of ﬂavonoids that occurred during
incubation [67]. The ﬂavonoid nature of the peaks was
experimentally conﬁrmed by the same elution times and
absorbance spectra of incubated ﬂavonoid alone and by the
absence of protein band on SDS gel for the concentrated
fraction sample from SEC-HPLC (data not shown).
The elution proﬁles of α-synuclein incubated in the pres-
ence of inhibitory ﬂavonoids had six major peaks. Besides
the monomer and ﬂavonoid peaks, peaks corresponding to
dimer (11mL), trimer (10.3mL), and small (7.8mL) and
large oligomer (6.2mL) were detected (Figure 8). Because
of the ﬂavonoid interference with the protein spectra, the
protein nature of the peaks and the amount of protein
eluted was analyzed by SDS-PAGE. The increased intensity8 Parkinson’s Disease
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Figure 8: SEC-HPLC proﬁles of the supernatants of α-synuclein
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of the monomer peak was mostly attributed to the elevated
amount of monomers and partially to the absorbance
of ﬂavonoid tightly bound to the monomer. Absorbance
intensity of dimer and oligomer peaks also partially cor-
responded to the ﬂavonoid absorbance and indicated the
stability of ﬂavonoid-protein complexes. The observation
of oligomeric species on HPLC conﬁrms that ﬂavonoid-
inducedoligomersaremorestableandthusdiﬀerentfromα-
synuclein oligomers obtained without ﬂavonoids that easily
dissociate and are not detected by HPLC.
Interestingly, Figure 8 also shows that the distribution
of oligomeric forms and monomers varied depending on
the nature of ﬂavonoid. For example, eriodyctiol mostly
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Figure 9: Secondary structure analyses of α-synuclein in the
presence of baicalein by ATR-FTIR (red lines). The spectra of
α-synuclein alone before and after incubation was presented for
comparison (black lines).
stabilized dimers and monomers, G-500 mostly monomers,
and baicalein mostly oligomers and monomers.
All inhibitory ﬂavonoids aﬀected α-synuclein aggrega-
tion and lead to the inhibition of ﬁbril formation, accumu-
lation of oligomeric species, and stabilization of monomers
and oligomers. Therefore, at the next stage, we analyzed
the conformational properties of ﬂavonoid-stabilized α-
synuclein species. To this end, attenuated total reﬂectance
FTIR was applied to detect the secondary structure of
ﬂavonoid-stabilized soluble species of α-synuclein. The FTIR
spectrum of fresh α-synuclein with baicalein exhibits a
typicalunfoldedstructure,similartofreshα-synucleinalone,
with the peak centered at 1652cm−1 (Figure 9, solid lines).
After 3 days of incubation, the spectrum of the protein alone
changed into a structure with signiﬁcant β-sheet, with the
peak at 1630cm−1, indicative of ﬁbril formation (Figure 9,
black lines), whereas the spectrum of the protein with the
compound did not exhibit signiﬁcant structural changes
(Figure 10, red lines), reﬂecting that baicalein inhibits α-
synuclein ﬁbrillation by stabilizing the natively unfolded
conformation of the protein.
3.3.AnalysisofFlavonoidInhibitoryEﬀectsonVariousStagesof
Fibrillogenesis. The inhibition of α-synuclein ﬁbrillogenesis
byﬂavonoidsmayinvolvetwodiﬀerentevents,theinhibition
of nucleus formation occurring during lag time or the
inhibition of ﬁbril elongation corresponding to the linear
increase in the ThT ﬂuorescence intensity. To resolve it,
one of the strong inhibitory ﬂavonoids, 6-HP, was added at
various times during incubation of α-synuclein. As shown
on Figure 10(a), 6-HP stopped the progress of ﬁbrillation
regardless of the time it was added, namely, at 0 hour
(sample L0), 12 hours (end of nucleation, sample L1), 21
hours (middle of elongation, sample L2), and 33 hours (endParkinson’s Disease 9
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Figure 10: The eﬀect of baicalein on α-synuclein ﬁbrillation
at diﬀerent stages by monitoring the kinetics of α-synuclein
ﬁbrillation (a) and the SDS-PAGE of the supernatants at the end
of reaction (b) for the sample with baicalein added at various times,
thatis,0hour(sampleL0),12hours(endofnucleation,sampleL1),
21 hours (middle of elongation, sample L2), and 33 hours (end of
elongation, sample L3).
of elongation, sample L3). Addition of 6-HP at any time
duringnucleationresultedinthecompleteinhibitionofﬁbril
formation. This indicated that 6-HP could act on the late
steps of nucleation such as formation of oligomers. When 6-
HP was added during linear growth of ﬁbrils or at the end of
ﬁbrillation, the decrease in ThT intensity and disaggregation
of formed ﬁbrils were observed. The initial drop was mostly
due to the quenching of ThT ﬂuorescence by the ﬂavonoid,
and the subsequent decrease in ThT signal was due to disag-
gregation of the existing ﬁbrils. This was conﬁrmed by EM
and SDS-PAGE. The rates of disaggregation were similar and
did not depend on time of ﬂavonoid addition. It was consis-
tent with explanation that the ﬁbrillar species were similar in
structure and mechanism of disaggregation was the same.
SDS-PAGE of α-synuclein supernatant fractions with 6-
HP added at various times of incubation was run to verify
the results of ThT assays (Figure 10(b)). SDS-PAGE analy-
sis demonstrated the considerable build-up of monomers,
dimers, trimers, and higher MW oligomers as long as the
addition of 6-HP was prior to nucleation (samples L0, L1).
This indicated that the most eﬃcient inhibition took place
during, or prior to, nucleation. When 6-HP was added after
the nucleation in the middle of or at the end of ﬁbril
elongation (L2 and L3), less amount of monomers and
oligomers was detectable.
Similar results were observed for α-synuclein with other
strong inhibitory ﬂavonoids such as baicalein, EGCG, and
T-415. It can be concluded that the inhibitory ﬂavonoids
stopped the progress of ﬁbrillation at any stage. Impor-
tantly, the addition of ﬂavonoids to the preformed ﬁbrils
resulted in almost complete ﬁbril disaggregation. However,
the most eﬃcient inhibition of α-synuclein ﬁbrillation
by the ﬂavonoids took place on or prior to nucleation
through formation of the ﬂavonoids-stabilized monomeric
and oligomeric forms of the protein.
3.4. Structural Features of α-Synuclein Fibrillation Inhibitors.
Our results showed that a variety of ﬂavonoids can inhibit
the ﬁbril formation of α-synuclein. Some ﬂavonoids can
also disaggregate existing ﬁbrils. Among the 48 ﬂavonoids
tested, several compounds exhibited stronger inhibitory
eﬀects than others despite the overall structural similarity of
the ﬂavanoid family. The aim of this study was to eventually
elucidate the relationship between the molecular structure of
a series of structurally related ﬂavonoids and their ability to
inhibit α-synuclein ﬁbrillation.
The molecular structural requirements that appear nec-
essarytoprovideaﬂavonoidtheabilitytoinhibitα-synuclein
ﬁbrillation were determined to be a vicinal dihydroxyphenyl
moiety. In another words, ﬂavonoids without any vicinal
dihydroxyphenyl moieties have no inhibitory eﬀect on α-
synuclein ﬁbrillation.
The substitution pattern, that is, the ring to locate in
and the position on the ring, of the dihydroxyl groups
could also aﬀect the inhibitory activity but not necessarily.
For example, comparisons were made among the following
5ﬂ a v o n e s( Figure 11(a)). The 2 ﬂavones, D-258 with the
3 ,4 -dihyhroxy substitution pattern on ring B, and D-406
with the 2 ,3 -dihyhroxyl group in ring B, have a similarly
good inhibitory eﬀect on α-synuclein ﬁbrillation. Rather
than the o-dihydroxy structure in the B ring, the other 2
ﬂavones, D-112 and 22-357, have hydroxyl substituents in
a catechol structure on the A ring at diﬀerent positions.
The 2 compounds also have a similar inhibitory eﬀect on α-
synuclein ﬁbrillation, but weaker than the eﬀect from D-258
and D-406. In contrast to the above 4 ﬂavones, D-407 does
not have a vicinal dihydroxyphenyl moiety, nor does it have
any inhibitory eﬀect on α-synuclein ﬁbrillation (see activity
in Supplementary Table S1).
Moreover, the diﬀerence in the number of vicinal dihy-
droxyl substituents and the number of individual hydroxyl
groups alsobrings some diﬀerencein the inhibitory activities10 Parkinson’s Disease
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of ﬂavonoids. Generally, the larger the number, the stronger
it is. For instance, the 4 ﬂavonols, T-601, 22-344, quercetin,
and G-500, all of them have the 3 ,4 - dihyhroxy substi-
tution pattern on ring B, (Figure 11(b)) conferring them
the inhibitory activity. However, T-601 does not have any
individual hydroxyl group in the A ring, 22-344 has one
single hydroxyl group in ring A, quercetin has 2 individual
hydroxyl groups in ring A, and G-500 has 3 hydroxyl groups
with 2 of them adjacent. Not surprisingly, the inhibitory
activity is in the increasing order of T-601 < 22-344 <
quercetin < G-500 (data not shown).
Flavonoids with three vicinal hydroxyl groups exhibited
the enhanced inhibitory eﬀects on α-synuclein ﬁbrillation
(structures in Figure 12). For example, 6-HP exhibited
strongerinhibitoryactivitythan22-357(Figure 2);myricetin
was stronger than quercetin, and tricetin was stronger than
luteolin (data not shown). Interestingly, all the ﬂavonoids
(except 021037) with three vicinal hydroxyl groups from
our screening were found to be strong inhibitors, that is,
completely inhibited the ﬁbril formation within 3 days of
incubation (Figure 13(a)). The essentially weaker inhibitory
eﬀects of 021037 could result from the lack of 2,3-double
bond in this ﬂavonoid. On the other hand, only three
ﬂavonoids without three vicinal hydroxyl groups from this
screening were found to exhibit strong inhibitory eﬀect
on α-synuclein ﬁbrillation. They were as follows: T-415 an
isoﬂavonoid, eriodictyol a ﬂavanone, and 22-324 a ﬂavone
(Figure 13(b)).
Inversely, the ﬂavonoids with structures exactly the same
or very similar (the number and position of ring substitu-
tions) to those of strong inhibitors, but with hydroxyl groups
replaced by methoxyl groups, did not have any inhibitory
eﬀects on α-synuclein ﬁbrillation, as exempliﬁed by the
following pairs of ﬂavonoids H-114 versus 6-HP and 22-
324 versus 22-323 (Figure 14). The details of the molecular
mechanisms underlying the ﬂavanoid-induced inhibition
of α-synuclein ﬁbrillation were analyzed recently [68]. It
was shown that the noncovalent binding of the inhibitory
ﬂavonoids to α-synuclein and the covalent modiﬁcation
by the ﬂavonoid quinone led to the restriction of the
conformationalchangesinthisnativelyunfoldedproteinand
to the stabilization of soluble ﬂavonoid-modiﬁed species ofParkinson’s Disease 11
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α-synuclein (monomers and oligomers). All of these factors
rather than a single one contribute to the inhibition of α-
synuclein ﬁbrillation induced by the ﬂavonoid. The struc-
tural requirements for ﬂavonoid to be a good inhibitor of α-
synuclein ﬁbrillation were vicinal dihydroxyphenyl moieties,
irrespectively of their positions in the rings. Flavonoids with
three vicinal hydroxyl groups exhibited enhanced inhibitory
eﬀects on α-synuclein ﬁbrillation. The antioxidant activities
of ﬂavonoids were generally correlated with their in vitro
inhibitory eﬀects on α-synuclein ﬁbrillation [68].
3.5. Implications for the Treatment of PD. PD has a multifac-
torial etiology depending on genetic susceptibility and envi-
ronmental factors. From epidemiological and environmental
studies, oxidative stress, transition metal accumulation, and
inﬂammation appear to play a role in the pathology of PD.
However, the detailed molecular mechanisms of triggering
theoxidativestressaswellastargetsoftransitionmetalaction
are not known. The cause of inﬂammation is also unknown.
From genetic etiological studies, α-synuclein misfolding and
aggregation as well as impairment in the cellular folding
machinery appear to be important in the early onset of PD.
However, functions of α-synuclein, a cause of protein aggre-
gation, and its role in the triggering of neurodegeneration
are still unknown. Recently, it has been proposed that α-
synuclein may interact with mitochondrial membranes and
aﬀects their structures. This interesting idea may consolidate
genetic and environmental studies of PD etiology. α-
Synuclein could be a key factor, upon which oxidative stress
or transition metals act resulting in protein aggregation
or oligomerization that in turn aﬀect mitochondrial
membranesleadingtomitochondrialdysfunctionsincluding
elevated ROS production, leakage of cellular membrane
compartments, cell death, and inﬂammation. Therefore, the
prevention of protein aggregation and oligomerization is
an attractive strategy in combating the neurodegeneration12 Parkinson’s Disease
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because it acts on the very beginning of the proposed
cellular pathway leading to cell death. In our study, we
analyzed 48 ﬂavonoids for their eﬃciency to inhibit α-
synuclein aggregation in vitro by stabilizing nonpathogenic
protein conformations. Majority of the ﬂavonoids inhibit α-
synuclein polymerization either delaying or completely abol-
ishing ﬁbril formation. The thermodynamic distributions of
α-synuclein species are tremendously altered in the presence
of strong ﬂavonoid inhibitors. Flavonoids such as 6-HP,
eriodictyol, G-500, and baicalein tightly bind to the protein
and greatly stabilize its natively unfolded conformation. The
major species existing in the thermodynamic equilibrium
in the presence of ﬂavonoids are oligomers and monomers.
Flavonoid compounds show diﬀerent ratios in distribution
of monomers and oligomers indicating that they stabilize
mostly either monomeric or oligomeric conformations.
Most importantly, strong inhibitors disaggregate preformed
ﬁbrils.
Substantial evidence reveals that ﬂavonoids act in vivo as
health-beneﬁcial and neuroprotective agents. For example,
baicalein, a typical ﬂavonoid compound, is the main com-
ponent of a traditional Chinese herbal medicine Scutellaria
baicalensis.Recentstudieshaveshownthatbaicaleinprotects
rat cortical neurons from amyloid β-induced toxicity by
its inhibition of lipoxygenase [69]. Natural medicines
containing these compounds have been reported to have
beneﬁcial eﬀects in treating memory loss and dementia
[70, 71]. Another ﬂavonoid, (−)-epigallocatechin-3-gallate
(EGCG), has been shown neuroprotective in an MPTP-
induced animal model of dopaminergic degeneration
[64]. Their data from the yeast model also demonstrated
that ﬂavonoids counteract the cytotoxic properties of
α-synuclein toxicity directly in a cellular context [65].
Epidemiological studies suggest an inverse relation between
ﬂavonoid intake and incidence of chronic diseases, such
as coronary heart disease [72–74], as well as dementia and
other neurodegenerative diseases [63, 70].
However, little is currently known about the mechanism
ofﬂavonoidactioninvivo.Therearetwomodelsthatexplain
the ﬂavonoid health beneﬁcial eﬀects. First model suggests
that the antioxidant properties of ﬂavonoids are important
in combating oxidative stress by scavenging radicals and by
metal chelation. However, even with very high ﬂavonoid
intakes, plasma and intracellular ﬂavonoid concentrations
in humans are likely to be 100–1,000 times lower than
concentrations of other antioxidants, such as ascorbate or
glutathione. Furthermore, most circulating ﬂavonoids are
actually ﬂavonoid metabolites, some of which have lower
antioxidant activity than the parent ﬂavonoid. For these
reasons, the relative contribution of dietary ﬂavonoids to
plasma and tissue antioxidant function is most likely to be
relatively minor [75, 76].
The second model postulates that many of the biological
eﬀects of ﬂavonoids can be related to their ability to
modulate cell-signaling pathways rather than to act as
antioxidants. For instance, several signaling mechanisms
were suggested to explain polyphenol-induced protection
against amyloid cytotoxicity [77] and the neuroprotective
eﬀects of ﬂavonoids [78]. The validity of the hypothesis
is supported by the facts that intracellular concentrations
of ﬂavonoids required to aﬀect cell signaling pathways are
considerably lower than those required to impact cellular
antioxidant capacity, and ﬂavonoid metabolites may still
retain their ability to interact with cell signaling proteins,
even if their antioxidant activity is diminished.
Our results have demonstrated that ﬂavonoids signif-
icantly aﬀect α-synuclein propensity to aggregate in vitro
through binding and stabilizing the certain protein confor-
mations. This direct act of ﬂavonoids on protein aggregation
is a highly possible mechanism of ﬂavonoid action in vivo.
The apparent Kd of ﬂavonoid-α-synuclein complexes is in
range of 200–800nm, which is suﬃcient for binding of
ﬂavonoids in vivo [68]. Furthermore, there is a certain
correlation between antioxidant activities of ﬂavonoids and
their in vitro inhibitory eﬀects on α-synuclein ﬁbrillation;
thus it is possible that the antioxidant potential of ﬂavonoids
may relate not only to the scavenging of radicals and
metals but also to binding to amyloidogenic proteins such
as α-synuclein, locking the certain protein structures, and
abolishing protein aggregation.
It has been suggested that the precursors of ﬁbrils, the
transient oligomers, and protoﬁbrils on the aggregation
pathway in neurodegenerative diseases might be more toxic
than ﬁbrils [21, 22]. Hence, it can be argued that the
ﬂavonoid-induced oligomers from our study could be more
cytotoxic than ﬁbrils. Several studies have been done to test
the cytotoxicity of one of the ﬂavonoid-synuclein complexes,
the baicalein-stabilized oligomers, and have demonstrated
their benign eﬀects on membrane permeability [38], cell
culture toxicity [79] ,a n dn e u r o nd e g e n e ra t i o ni nw o rm sa n d
mice. Masuda et al. have reported that, unlike α-synuclein
ﬁbrils and protoﬁbrils, ﬂavonoid-induced soluble oligomeric
species did not reduce the viability of human dopaminergic
neuroblastoma SH-SY5Y cells [79]. These ﬁndings suggest
that the soluble oligomers formed in the presence of
inhibitory ﬂavonoids may not be toxic to human neurons
and that these ﬂavonoids may therefore have therapeutic
potential for PD and other amyloidoses.
Flavonoids are among the most secure and reliable sub-
stances available now for preventing various diseases includ-
ing maladies related to the oxidative-stress and neurodegen-
eration. In this study, we have demonstrated that ﬂavonoids
can directly act on aggregation of α-synuclein, being able to
inhibitﬁbrillationanddisaggregatethepreformedﬁbrilsinto
monomers and nonpathogenic oligomers. This implies that
ﬂavonoids may have been already combating PD, and that
diets rich in ﬂavonoids may be eﬀective in preventing and
curing the disorder.
Supporting Information Available
Experimental details of the inhibitory activities of each
ﬂavonoid analyzed in this study are available; the ﬁgures
illustrate instant changes in the intensity of ThT ﬂuorescence
upon adding 50μM ﬂavonoids directly to the existing α-
synuclein ﬁbril solution. This material is available free of
charge via the Internet at http://pubs.acs.org.14 Parkinson’s Disease
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